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About half of idiopathic retroperitoneal ﬁbrosis might be classiﬁed as a IgG4-related disease, a newly
characterized disease that is especially known to be sensitive to steroid therapy. We developed a new
protocol for diagnosis and treatment of retroperitoneal ﬁbrosis, which included aggressive diagnosis of IgG4-
related disease. We retrospectively reviewed 22 cases with idiopathic retroperitoneal ﬁbrosis that were
diagnosed and treated according to our protocol. Of them, 10 patients (45.5%) had no evidence of IgG4-
related disease (non-IgG4RD group), whereas 12 patients (54.5%) were diagnosed with IgG4-related disease
(IgG4RD group). All patients received steroid therapy, and 13 patients (59.1%) underwent ureteral stenting
or received prednisolone (PNS). There was no severe adverse event and planned steroid therapy was
completed in all patients. In principle, maintenance steroid therapy was continued after induction therapy
in the IgG4RD group, whereas steroid therapy was discontinued in the non-IgG4RD group. Regression of
retroperitoneal plaque was achieved in all 22 patients. Four (57.1%) out of 7 patients and 3 (50.0%) out of 6
patients achieved freedom from ureteral stent or PNS in the non-IgG4RD group and IgG4RD group,
respectively. All 3 patients with PNS became catheter-free after treatment, whereas only 4 (40.0%) of the 10
patients with ureteral stent could become stent-free. Steroid therapy could be discontinued in 7 patients
(70.0%) in the non-IgG4RD group. The results of this study suggest that similar efﬁcacy of steroid therapy
can be expected in the non-IgG4RD group and IgG4RD group.
(Hinyokika Kiyo 63 : 449-454, 2017 DOI : 10.14989/ActaUrolJap_63_11_449)
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(2）血液学的に高 IgG4 血症（135 mg/dl 以上）を認める．
(3）病理組織学的に以下の所見をいずれも認める．
○1著明なリンパ球，形質細胞の浸潤と線維化を認める．
○2 IgG4 陽性形質細胞浸潤が IgG4/IgG 陽性細胞比40％





導入 プレドニゾロン 0.6 mg/kg/day（40 または 30 mg/
day）， 4週間
↓









Fig. 2. Protocol of steroid therapy for idiopathic
retroperitoneal ﬁbrosis with no ﬁnding
suggestive of IgG4-related disease.
1．ステロイド治療終了後の再燃
再導入 プレドニゾロン 20 mg/day， 4週間
↓





プレドニゾロンを再燃時の投与量＋10 mg へ増量， 2週間
↓
以降 1週ごと 5 mg/day ずつ減量
↓
維持療法
5 mg/day 6カ月間＋2.5 mg/day 6カ月間
Fig. 3. Protocol of steroid therapy for relapsed idio-
pathic retroperitoneal ﬁbrosis. 1) Relapse
after completion of initial steroid therapy
and 2) relapse during initial steroid therapy.



















例は非 IgG4 関連疾患として扱った．IgG4 関連疾患
と診断された症例は当院内科でステロイド治療が行わ
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値（範囲) 65（53-79) 60（40-80) 0.248






行，n（％) 0（0％) 9（75.0％) ＜0.001










央値（範囲) 29.5（1-53) 48（8-73) 0.21
プラークの縮小，
n（％) 10（100％) 12（100％) 1
尿管ステント/PNS




n（％) 2（20.0％) 0（0％) 0.128
Table 4. Details of patients without diagnosis of IgG4-related disease










1 67 女 NA 左 ― 13 離脱 ―
2 62 男 94.5 右 経皮的腎瘻 13 離脱 可
3 79 男 92.6 右 ― 12 離脱 ―
4 62 男 153 左 経皮的腎瘻 14＋6（再燃後)
再燃
再治療後離脱 可 CMV 感染症，骨粗鬆症
5 71 男 176 右 尿管ステント 14 離脱 可
6 55 男 30.6 左 尿管ステント 16 離脱 可
7 53 女 NA 左 ― 12 離脱 ―
8 78 男 114 両側 尿管ステント 12＋6（再燃後)
再燃
再治療終了 不可
9 63 女 NA 左 尿管ステント 12 終了 不可
10 76 男 NA 両側 尿管ステント 12 終了 不可











2群間の比較には Fisher’s exact test，Mann-Whitney
U test を用い，p 値 0.05 未満を統計学的有意差あり
とした．
結 果
非 IgG4 関連疾患および IgG4 関連疾患両群の患者
背景，および治療成績を Table 2 に示す．診断時年
齢，男女比に両群間で有意な差はなかった．尿管ステ
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